Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke

Charlotte Zerna; Götz Thomalla; Bruce C V Campbell; Joung-Ho Rha; Michael D Hill

doi:10.1016/S0140-6736(18)31874-9

Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke

Standard

Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. / Zerna, Charlotte; Thomalla, Götz; Campbell, Bruce C V; Rha, Joung-Ho; Hill, Michael D.

In: LANCET, Vol. 392, No. 10154, 06.10.2018, p. 1247-1256.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Zerna, C, Thomalla, G, Campbell, BCV, Rha, J-H & Hill, MD 2018, 'Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke', LANCET, vol. 392, no. 10154, pp. 1247-1256. https://doi.org/10.1016/S0140-6736(18)31874-9

APA

Zerna, C., Thomalla, G., Campbell, B. C. V., Rha, J-H., & Hill, M. D. (2018). Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. LANCET, 392(10154), 1247-1256. https://doi.org/10.1016/S0140-6736(18)31874-9

Vancouver

Zerna C, Thomalla G, Campbell BCV, Rha J-H, Hill MD. Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. LANCET. 2018 Oct 6;392(10154):1247-1256. https://doi.org/10.1016/S0140-6736(18)31874-9

Bibtex

@article{bd650d7558d94abbb1a5d04f1290fb14,

title = "Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke",

abstract = "Even though stroke presents as a variety of clinical syndromes, neuroimaging is the most important biomarker to help differentiate between stroke subtypes and assess treatment eligibility. Therapeutic advances have led to intravenous thrombolysis with tissue-type plasminogen activator and endovascular treatment for proximal vessel occlusion in the anterior cerebral circulation being standard care for acute ischaemic stroke. Providing access to this care has implications for existing systems of care for stroke and their organisation and has reintroduced the possibility of adjuvant and neuroprotective treatment strategies in acute ischaemic stroke. The use of neuroimaging for patient selection and speed of diagnosis and delivery of treatment are the dominant themes of modern ischaemic stroke care.",

keywords = "Brain Ischemia, Emergency Service, Hospital, Endovascular Procedures, Humans, Neuroimaging, Stroke, Thrombolytic Therapy, Time Factors, Tissue Plasminogen Activator, Transportation of Patients, Journal Article, Review",

author = "Charlotte Zerna and G{\"o}tz Thomalla and Campbell, {Bruce C V} and Joung-Ho Rha and Hill, {Michael D}",

year = "2018",

month = oct,

day = "6",

doi = "10.1016/S0140-6736(18)31874-9",

language = "English",

volume = "392",

pages = "1247--1256",

journal = "LANCET",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "10154",

}

RIS

TY - JOUR

T1 - Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke

AU - Zerna, Charlotte

AU - Thomalla, Götz

AU - Campbell, Bruce C V

AU - Rha, Joung-Ho

AU - Hill, Michael D

PY - 2018/10/6

Y1 - 2018/10/6

N2 - Even though stroke presents as a variety of clinical syndromes, neuroimaging is the most important biomarker to help differentiate between stroke subtypes and assess treatment eligibility. Therapeutic advances have led to intravenous thrombolysis with tissue-type plasminogen activator and endovascular treatment for proximal vessel occlusion in the anterior cerebral circulation being standard care for acute ischaemic stroke. Providing access to this care has implications for existing systems of care for stroke and their organisation and has reintroduced the possibility of adjuvant and neuroprotective treatment strategies in acute ischaemic stroke. The use of neuroimaging for patient selection and speed of diagnosis and delivery of treatment are the dominant themes of modern ischaemic stroke care.

AB - Even though stroke presents as a variety of clinical syndromes, neuroimaging is the most important biomarker to help differentiate between stroke subtypes and assess treatment eligibility. Therapeutic advances have led to intravenous thrombolysis with tissue-type plasminogen activator and endovascular treatment for proximal vessel occlusion in the anterior cerebral circulation being standard care for acute ischaemic stroke. Providing access to this care has implications for existing systems of care for stroke and their organisation and has reintroduced the possibility of adjuvant and neuroprotective treatment strategies in acute ischaemic stroke. The use of neuroimaging for patient selection and speed of diagnosis and delivery of treatment are the dominant themes of modern ischaemic stroke care.

KW - Brain Ischemia

KW - Emergency Service, Hospital

KW - Endovascular Procedures

KW - Humans

KW - Neuroimaging

KW - Stroke

KW - Thrombolytic Therapy

KW - Time Factors

KW - Tissue Plasminogen Activator

KW - Transportation of Patients

KW - Journal Article

KW - Review

U2 - 10.1016/S0140-6736(18)31874-9

DO - 10.1016/S0140-6736(18)31874-9

M3 - SCORING: Review article

C2 - 30319112

VL - 392

SP - 1247

EP - 1256

JO - LANCET

JF - LANCET

SN - 0140-6736

IS - 10154

ER -